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Context: Osteoporosis and fractures are prevalent after orthotopic liver transplantation (OLT), but
data on these skeletal complications are scarce in patients with end-stage liver disease awaiting
liver transplantation.
Objective: To evaluate the prevalence of vertebral fractures (VFs) in OLT recipients at the time of
screening for transplantation and to establish the association between bone mineral density (BMD)
and these fractures before transplantation.
Design and Setting: We conducted a retrospective study of consecutive OLT recipients at the Leiden
University Medical Centre between 2000 and 2011 at the time of screening for transplantation.
Clinical, laboratory, and BMD data were extracted from electronic hospital records. Conventional
spinal radiographs were assessed for VF by two independent observers using Genant’s semiquan-
titative method.
Patients: In total, 162 of the 223 OLT recipients (median age, 51 y; 75% men) who had available
BMD and spinal radiographs but who were not receiving bone-modifying treatment at screening
for OLT were included in the study.
Main Outcome Measures: Association between BMD and VF before transplantation.
Results: Osteoporosis and osteopenia were prevalent at the lumbar spine in 19 and 38% of subjects,
respectively, and in 10 and 42 % at the femoral neck. VFs, mostly grade 1, were prevalent in 56%
of the subjects. There was no association between BMD and prevalent VF before transplantation.
Conclusions: VFs were prevalent in liver transplant recipients at the time of screening for trans-
plantation, but there was no association between BMD and prevalent fractures. Spinal radiographs
should be routinely performed as part of screening protocols before liver transplantation to enable
identification of VF and allow timely intervention to potentially decrease or prevent skeletal
morbidity after transplantation. (J Clin Endocrinol Metab 99: 3677–3685, 2014)
Osteoporosis and fractures are common after livertransplantation (1–3), but data on these skeletal
complications are scarce in patients with end-stage liver
disease awaiting orthotopic liver transplantation (OLT)
(2, 4–6). Published data suggest low bone mass in over
50% of patients and prevalent vertebral fractures varying
from 3.5 to 36% of patients before transplantation, de-
pending on the method used for identification of these
fractures (1, 4, 5, 7, 8). The liver plays an important role
in bone and mineral metabolism. The etiology of bone loss
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.
Copyright © 2014 by the Endocrine Society
Received February 16, 2014. Accepted July 16, 2014.
First Published Online July 24, 2014
* B.v.H. and N.A.T.H. are joint senior authors.
Abbreviations: BMD, bone mineral density; CI, confidence interval; INR, international nor-
malized ratio; LS, lumbar spine; MELD, Model for End-stage Liver Disease; 25-OHD, 25-
hydroxyvitamin D; OLT, orthotopic liver transplantation; OR, odds ratio.
O R I G I N A L A R T I C L E
E n d o c r i n e C a r e
doi: 10.1210/jc.2014-1469 J Clin Endocrinol Metab, October 2014, 99(10):3677–3685 jcem.endojournals.org 3677
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 05 October 2014. at 23:08 For personal use only. No other uses without permission. . All rights reserved.
and increased fracture risk associated with disturbed liver
function is multifactorial, including vitamin D deficiency,
hypogonadism, decreased mobility, corticosteroid use (in
autoimmune hepatitis), and alcohol toxicity where rele-
vant. Candidates for liver transplantation with underlying
skeletal pathology are potentially at higher risk for skeletal
morbidity, particularly increased fracture risk, after trans-
plantation (1, 2, 9). Cholestatic liver disease has been re-
ported to be associated with osteoporosis and vertebral
fractures (10–12), and alcohol abuse is a common cause of
osteoporosis and increased fracture risk, particularly in
men (5, 13), but less is known about these skeletal com-
plications in other liver pathologies.
Prevalent vertebral fractures represent an important
predictive factor for future fractures (1, 2, 14). Indeed,
data show that risk of future fracture significantly in-
creases with increasing number and/or grade of severity of
vertebral fractures, also shown to be true for mild grade 1
vertebral fractures (15). Identification of these fractures
before transplantation would thus be of significant clinical
relevance, not only to predict future fracture risk, but also
to allow timely initiation of therapeutic interventions po-
tentially able to decrease or prevent skeletal morbidity
after transplantation.
The main objectives of our study were to evaluate the
prevalence of vertebral fractures in liver transplant recip-
ients at the time of screening for transplantation and to
establish the association between bone mineral density
(BMD) and these fractures before transplantation.
Patients and Methods
Patients
Consecutive patients who underwent a first OLT at the Le-
iden University Medical Centre between January 2000 and Jan-
uary 2011 and who had available BMD measurements and con-
ventional radiographs of the thoracic and lumbar spine (LS),
performed at the time of their extensive in-hospital screening
program before liver transplantation, were eligible for inclusion
in the study. Patients treated with corticosteroids or bisphos-
phonates before or at the time of screening for transplantation
were excluded from the present analysis because of the bone-
modifying nature of these therapeutic agents. The Leiden Uni-
versity Medical Centre is a tertiary referral center for liver dis-
eases, and often our first encounter with most patients is only at
the time of screening for liver transplantation. Correction of
vitamin D deficiency and treatment of osteoporosis with bone-
modifying agents such as bisphosphonates has thus been very
variable, despite clear guidelines, and is highly dependent on the
clinical judgment of the referring physician, rather than being
dictated by a specific protocol.
Methods
Demographic, clinical, laboratory, and BMD data at the time
of screening before liver transplantation were obtained from
electronic hospital records of individual patients. Availability of
conventional spinal radiographs was ascertained from the re-
cords. Nonvertebral fractures were poorly documented, so that
data on these fractures could not be analyzed.
Demographic data
Data on age, gender, smoking, height, weight, and primary
liver disease were documented. Data on medication including the
use of corticosteroids, calcium and vitamin D supplements, and
bone-modifying agents such as bisphosphonates were recorded.
Biochemical investigations
Biochemical data extracted from the patients’ records in-
cluded serum calcium (corrected for an albumin of 40 g/L), phos-
phate, creatinine, total bilirubin, anticoagulant international
normalized ratio (INR), PTH, and 25-hydroxyvitamin D (25-
OHD) concentrations. Severity of liver disease was determined
using the laboratory-based Model for End-stage Liver Disease
(MELD) score, shown to be correlated with 3-month survival
after transplantation in patients with cirrhosis. Scores were cal-
culated on the basis of serum measurements of bilirubin, creat-
inine, and INR in SI units, using the following accepted formula
(16):
MELD  100.957lnCreatinine/88.4
 0.378lnBilirubin/17.1  1.12lnINR  6.43
BMD measurements
BMD was measured at the LS and the femoral neck (FN) using
dual energy x-ray absorptiometry (Hologic QDR 4500; Hologic
Inc; equipped with reference values based on the National Health
and Nutrition Examination Survey [NHANES III]). Data col-
lected included absolute measurements of BMD in g/cm2, T-
scores (SD above or below that of a young adult reference pop-
ulation at peak bone mass), and Z-scores (SD above or below
that of an age- and sex-matched reference population). World
Health Organization criteria were used to define osteoporosis:
T-score of 2.5 or less; and osteopenia, T-score between 1 and
2.5 SD.
Due consideration was given to the need to adjust mean BMD
scores of the LS in the presence of one or more lumbar vertebral
fractures at the site of the LS BMD measurement (L1–L4).
Vertebral fracture assessment
Conventional anterior-posterior and lateral radiographs of
the thoracic spine and postero-anterior and lateral radiographs
of the LS were performed by an experienced radiology technician
using a standardized protocol, at a distance of 115 cm, with the
film centralized on Th7 for the thoracic spine and on L3 for the
LS.
All radiographs were blindly assessed for the presence and
severity (grade) of vertebral fractures by two independent ob-
servers, an experienced musculoskeletal radiologist (H.M.K.),
and an experienced bone and mineral disorders specialist
(N.A.T.H.). Fractures were assessed using Genant’s semiquan-
titative method of vertebral fracture assessment (17). Using this
method, a decrease in height of 20–25% is considered to be a
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“mild” grade 1 fracture, a decrease of 25–40% is a “moderate”
grade 2 fracture, and a decrease of  40% is a “severe” grade 3
fracture. Uniform loss of vertebral height compared to adjacent
vertebrae was additionally documented using the same grading
scores. Radiographs were assessed in a random order, using ran-
dom numbers generated by SPSS version 20 software (SPSS Inc).
A unique number was assigned to each series of radiographs
performed at screening for OLT. Radiographs were individually
scored by the two independent observers, and in case of discrep-
ancy in scores, mostly about fracture grading, consensus was
achieved by both observers reviewing the radiographs together.
Careful attention was given to the interpretation of vertebral
deformities, excluding vertebral height reductions or deformities
due to development abnormalities, degenerative changes, osteo-
chondritis (Scheuermann’s disease), or localized metabolic bone
disorders such as Paget’s disease of bone.
The study was approved by the Medical Ethics Committee of
the Leiden University Medical Centre.
Statistical analysis
For descriptive statistics, categorical variables were expressed
as numbers and as percentages. Data containing continuous vari-
ables were summarized using mean and SD in case of an esti-
mated normal distribution. Median and 5th and 95th percentiles
were used otherwise.
A regression model was used to evaluate the influence of po-
tential risk factors for the development of osteoporosis and for
the prevalence of vertebral fractures. A univariate regression
model was first used, followed by a multivariate regression
model with corrections for multiple variables including age and
sex. A linear regression model was used in case of continuous
variables and a logistic regression model in case of dichotomous
variables.
We chose to calculate odds ratios (ORs) rather than risk ratios
because of the regression models used. A P value  .05 was
considered significant.
We evaluated the direct effect of various risk factors, such as
cholestatic or alcoholic liver disease, on the outcome parameter,
such as prevalence of fractures, as well as the indirect effect of the
risk factor on the outcome of through various mediators, such as
vitamin D deficiency, using a logistic regression model. We cal-
culated confidence intervals (CIs) of the effect of mediators using
the bootstrap method.




In total, 162 of the 201 patients who received an elec-
tive OLT in the 10-year period between 2000 and 2011,
who had available BMD measurements and conventional
spinal radiographs performed at the time of screening be-
fore liver transplantation, but who were not treated with
bisphosphonates, corticosteroids, or other bone-modify-
ing agents were included in the study. Of the 39 excluded
patients, 21 had for logistics reasons no BMD measure-
ments and/or conventional spine radiographs at the time
of screening for OLT, and 18 patients were using bone-
modifying treatments. Details of patients included and ex-
cluded are shown in a study flow chart (Figure 1). Median
age for the total population studied was 51 years (range,
17–69 y), and 122 of the 162 patients (75%) were men.
Median age for women was also 51 years (range, 16–66
y), and 23 women were younger than 50 years. Meno-
pausal status was not documented. The most common
liver pathology was viral or alcoholic liver disease (31 and
Figure 1. Study flow chart. CS, corticosteroids; LT, liver transplantation.
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29%, respectively), followed by cholestatic liver disease
(14%). Eight percent of patients were using calcium and
vitamin D supplements, usually as a combination prepa-
ration at a fixed dose of 500 mg calcium and 400 IU chole-
calciferol, which had been initiated at some stage before
screening for transplantation. Details of patients’ charac-
teristics are shown in Table 1.
Biochemical data
Mean serum creatinine concentration was 89  47
mol/L (normal, 104 mol/L). Median bilirubin level
was 32 mol/L (range, 4–1172; normal, 17 mol/L).
Mean INR was 1.3  0.33. Mean 25-OHD level was 32 
23 nmol/L (normal, 50–250 nmol/L). 25-OHD levels
were also low, with a mean of 31  24 nmol/L in patients
using vitamin D supplements. Of the 162 patients studied,
110 patients had 25-OHD levels  50 nmol/L, of whom
54 patients had levels of  25 nmol/L. Mean laboratory
MELD score, reflecting the severity of liver disease, was
14  6 SD (range, 6–35).
BMD measurements
Osteoporosis and osteopenia were prevalent in 19 and
38% of patients at the LS, respectively, and in 11 and 42%
of patients at the FN. Mean T-score was 1.15  1.44 at
the LS and 1.06  1.23 at the FN. Mean Z-score was
0.63  1.49 at the LS and 0.15  1.21 at the FN.
Distributions of BMD at the LS and FN are shown for men
and women in Figure 2.
Factors associated with a low BMD
We evaluated a number of potential risk factors for low
BMD at the time of screening for transplantation (Table
2). Age and gender were not associated with increased risk
for osteoporosis. Cholestatic liver disease was associated
with significant increased risk for osteoporosis at the FN
in the univariate model (OR, 1.23; 95% CI, 1.07–1.41;
P  .004), but not in the multivariate model. There was no
indirect effect of cholestatic liver disease through vitamin
D deficiency on low bone mass (OR, 1.00; 95% CI, 0.96–
1.05). Compared to other liver pathologies, alcoholic liver
disease was not associated with an increased risk for low
bone mass at the LS in the multivariate model (OR, 0.27;
95% CI, 0.08–0.87; P  .028), an effect independent of
smoking (OR, 1.02; 95% CI, 0.98–1.06). Severity of liver
disease as reflected by the laboratory MELD score, was
associated with an increased risk of low bone mass at the
FN in both the univariate and multivariate models (mul-
tivariate model, OR, 1.15; 95% CI, 1.02–1.29; P  .021),
but not at the LS. Vitamin D deficiency (25-OHD levels
 25 nmol/L) was associated with an increased risk for
osteoporosis at the LS in the univariate model (OR, 1.16;
95% CI, 1.01–1.32; P  .029), but not in the multivariate
model or at the FN.
Prevalence of radiographic vertebral fractures
We documented 186 vertebral fractures in 90 patients,
representing a prevalence of 56%. Forty-three patients
(44%) had one prevalent fracture, 25 had two fractures
(15%), and 22 had three or more fractures (14%). Over
50% of patients had one or more mild grade 1 fractures
(52%), of whom 11 patients (10%) also had moderate
grade 2 fractures. None of the patients studied had severe
grade 3 vertebral fractures. The anatomical distribution of
the fractures is shown in Figure 3; 47 patients had lumbar
vertebral fractures, of whom 32 had one fracture, 24 of
which were of the first lumbar vertebra. Five patients had
two lumbar fractures, two patients had three, and two
patients had fractures of all four lumbar vertebrae. Most
of these fractures were single grade 1 fractures, with no
significant impact on total LS BMD, so that they were not
excluded from the analysis of total BMD.
Midthoracic compression fractures, usually involving
two or three vertebrae, most commonly thoracic vertebrae
7 to 9, were prevalent in seven patients (6%).
Factors associated with radiographic vertebral
fractures
We found no significant relationship between BMD
and prevalent vertebral fractures using either univariate or
Table 1. Characteristics of Patients at Time of
Screening for Liver Transplantation
Demographic Data
No. of patients 162
No. of male patients (%) 122 (75)
Age at time of screening, median
(5th–95th percentile), y
51 (30–65)
BMI, mean  SD, kg/m2 26  5
Smokers, n (%) 54 (35)
Primary liver disease, no. of patients (%)
Viral 50 (31)
Alcoholic 47 (29)
Combined alcoholic and viral 4 (2)
Cholestatic (PSC/PBC/overlap syndrome) 22 (14)
Malignancy 8 (5)
Autoimmune hepatitis 4 (2)
Metabolic 5 (3)
Othera 22 (14)
Severity of liver disease, mean lab MELD
score  SD
14  6
Bone-specific medication, no. of patients (%)
Calcium- and vitamin D supplements 12 (8)
Vitamin D supplements 2 (1)
Abbreviations: BMI, body mass index; PSC, primary sclerosing
cholangitis; PBC, primary biliary cirrhosis.
a Other primary liver disease including cryptogenic cirrhosis, malignant
tumor, vascular, rare metabolic disorders.
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multivariate analysis. In patients with prevalent fractures,
38% had a normal BMD, 40% had osteopenia, and only
23% had osteoporosis. There was no significant associa-
tion between BMD as a continuous variable, the presence
or absence of low BMD, and the presence or absence of
vertebral fractures, number of fractures per individual pa-
tient, or grade of severity of the fractures.
Male gender was associated with a higher prevalence of
vertebral fractures than female gender, with an OR of 4.10
(95% CI, 1.73–9.67; P  .001), independent of age, un-
Figure 2. Distribution of BMD in 40 women (upper panels) and 122 men (lower panels) with end-stage liver disease awaiting liver
transplantation. Middle, upper, and lower lines represent mean, 	 1, and 1 SD of an age- and sex-matched reference population, respectively.
Table 2. Risk Factors for Osteoporosis
Risk Factor
Univariate Multivariate
LS Osteoporosis FN Osteoporosis LS Osteoporosis FN Osteoporosis
OR (95% CI)
P
Value OR (95% CI)
P
Value OR (95% CI)
P
Value OR (95% CI)
P
Value
Male gender 1.03 (0.89–1.20) .660 0.88 (0.79–0.98) .025a 1.90 (0.62–5.82) .262 0.45 (0.13–1.55) .208
Age, y 1.00 (0.97–1.05) .675 1.00 (0.95–1.06) .885 1.03 (0.98–1.08) .216 0.99 (0.93–1.05) .726
Smoking 1.05 (0.92–1.20) .446 0.93 (0.85–1.03) .153 1.78 (0.69–4.60) .234 0.65 (0.15–2.77) .562
Cholestatic liver
disease
1.17 (0.97–1.42) .106 1.23 (1.07–1.41) .004a 1.38 (0.37–5.26) .631 2.00 (0.45–8.85) .363
Alcoholic liver
disease
0.89 (0.77–1.02) .086 0.91 (0.82–1.01) .070 0.27 (0.08–0.87) .028a 0.38 (0.07–2.16) .276
Vitamin D
deficiencyb
1.16 (1.01–1.32) .029a 1.01 (0.91–1.12) .827 2.10 (0.83–5.28) .116 0.73 (0.19–2.77) .645
Bilirubin level,
mmol/L
1.00 (1.00–1.00) .676 1.00 (1.00–1.00) .487
Serum creatinine,
mol/L
1.00 (0.99–1.01) .930 1.01 (1.00–1.01) .151 1.00 (0.99–1.01) .505 1.00 (0.99–1.01) .896
Lab MELD score 1.032 (0.976–1.0910) .531 1.10 (1.02–1.19) .012a 1.07 (0.97–1.19) .186 1.15 (1.02–1.29) .021a
a Significant effect, P value  .05.
b Vitamin D deficiency, 25-OHD level  25 nmol/L.
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derlying disease pathology, or severity of liver disease as
expressed by the laboratory MELD score (Table 3). Age as
a continuous parameter, vitamin D status, underlying liver
disease, and severity of liver disease were not associated
with an increased prevalence of vertebral fractures.
Discussion
Our data from this retrospective cohort study suggest a high
prevalence of vertebral fractures, mostly grade 1 fractures, in
56% of liver transplant recipients at the time of screening for
transplantation, independently of BMD measurements, al-
though low bone mass, predominantly osteopenia, was doc-
umented in about two-thirds of these patients. Thus, at the
time of screening for liver transplantation, there was no as-
sociation between BMD as a continuous variable or the pres-
ence or absence of low BMD and the presence or absence of
vertebral fractures, a higher number of fractures per individ-
ual patient, or a higher grade of fractures. Of all factors other
than BMD potentially associated with increased fracture
risk,onlymalegenderwasassociatedwith increased fracture
prevalence, independently of age, underlying liver disease, or
severity of liver failure. The absence of a significant associ-
ation between BMD and fracture prevalence suggests that
factorsaffectingbonequality, rather than justbonequantity,
may significantly contribute to fracture risk in patients with
end-stage liver failure.
Our findings are in keeping with previously published
studies, which report low bone mass in over 50% of pa-
tients awaiting liver transplantation, with the majority
having osteopenia and 20–40% having osteoporosis (2,
5, 7, 8, 10, 11, 18–21). A high prevalence of osteoporosis
and fractures reported in patients with cholestatic liver
disease (10–12) is believed to be due to vitamin D defi-
ciency and/or to the toxic effects of accumulated metab-
olites of cholestasis on bone remodeling. In our cohort,
cholestatic liver disease also represented an increased risk
for osteoporosis at the FN and for prevalent vertebral frac-
tures in univariate but not multivariate analysis. We did
not observe an increased prevalence of vertebral fractures
in patients with alcoholic liver disease, possibly because of
the removal of the inhibitory effect of alcohol on osteo-
blast function by the prerequisite alcohol abstinence for at
least 6 months before screening for transplantation, which
may also have contributed to the improvement in BMD at
the time of screening (22).
The high prevalence of vertebral fractures of 56% ob-
served in our cohort at the time of screening before trans-
plantation is much higher than the overall prevalence of
fractures of 7% observed in a recent Dutch population-
based cohort of men and women aged  55 years, in which
all subjects were screened by conventional spinal x-rays
(23). The observed prevalence of vertebral fractures in our
study was also higher than that of previously published
studies, which showed a widely variable and overall lower
prevalence of these fractures (3 to 36%), in patients await-
ing liver transplantation. (1–3, 5, 7, 8, 19, 24) The main
reason for this discrepancy in the prevalence of vertebral
fractures between our study and that of others probably
lies in the method used for the identification of these frac-
tures. Because vertebral fractures are often silent, actual
fracture prevalence may have been underestimated in
Figure 3. Distribution of 186 vertebral fractures in 90 patients with
end-stage liver failure awaiting liver transplantation; Th, thoracic
vertebra; L, lumbar vertebra.
Table 3. Risk Factors for Vertebral Fractures
Risk Factor
Univariate Multivariate
OR (95% CI) P Value OR (95% CI) P Value
Male gender 1.36 (1.14–1.62) .001a 4.10 (1.73–9.67) .001a
Age, y 1.02 (0.99–1.06) .136 1.03 (0.99–1.07) .093
Smoking 0.91 (0.77–1.08) .266 0.64 (0.30–1.38) .256
Cholestatic liver diseases 0.76 (0.61–0.95) .016a 0.33 (0.10–1.12) .076
Alcoholic liver disease 1.07 (0.86–1.42) .443 0.80 (0.35–1.86) .607
Lab MELD score 1.01 (0.96–1.07) .712 1.03 (0.96–1.11) .361
LS BMD, g/cm2 1.34 (0.21–8.21) .755 0.78 (0.10–5.96) .808
a Significant effect, P value  .05.
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studies in which spinal radiographs were only performed
in case of clinical suspicion of a vertebral fracture (5, 8, 25,
26). In contrast, conventional radiographs of the spine
formed an integral part of the pretransplantation workup
of our candidates for liver transplantation, and were con-
sequently available in all but a few patients. In our study,
we also judged it of clinical relevance to report grade 1
fractures, whereas mild grade fractures might have been
underreported in previous studies. This is partly because
radiologists have been generally reluctant worldwide to
report mild vertebral fractures, so that relying on radiol-
ogy reports for documentation of these fractures may have
resulted in an underestimate of their true prevalence (27,
28). Mild grade fractures may have also been consciously
under-reported because of doubt about their clinical rel-
evance, although these mild fractures have also now been
shown to be associated with increased fracture risk (15).
The relationship between BMD and prevalent fractures
has been poorly studied in patients awaiting liver trans-
plantation, and available data are not concordant. Some
studies thus show an association between low BMD and
prevalence of vertebral fractures (1, 29), but other studies
found no such association (3, 30). In our study, there was
intriguingly no association between BMD as a continuous
variable or as low vs normal BMD and fracture preva-
lence. Thirty-three percent of patients with fractures thus
had normal BMD, and 35% had osteopenia, suggesting
that factors affecting bone quality independently of BMD
may significantly contribute to increased skeletal fragility
in patients with advanced liver disease. This may have
significant implications in the management of skeletal
complications of advanced liver disease before and after
liver transplantation because tools to measure bone qual-
ity in vivo such as microindentation are just emerging and
remain to be validated, and data on means to specifically
improve bone quality with a view to decrease fracture risk
are yet to be established.
Notwithstanding, the accurate identification of preva-
lent vertebral fractures is essential in fracture risk assess-
ment because these fractures represent one of the strongest
predictors of subsequent vertebral and nonvertebral os-
teoporotic fractures (31, 32). There is also evidence that
mild grade 1 vertebral fractures are predictive for future
fracture risk (15). Of further clinical relevance is that up to
50% of vertebral fractures, even high grade fractures, may
be asymptomatic (34) and not necessarily associated with
a decrease in BMD, so that they may not come to the
attention of treating physicians. The small number of pa-
tients treated with bisphosphonates despite the high prev-
alence of osteoporosis and vertebral fractures and the
overall poor vitamin D status of patients awaiting liver
transplantation underscores the clinically unmet need for
treating physicians to address the issue of skeletal health in
patients with end-stage liver disease.
Our study has strengths as well as limitations. Its major
strength lies in the evaluation of consecutive transplant
recipients at the time of screening for transplantation in
one center over a 10-year period, providing a representa-
tive pretransplantation cohort with available BMD mea-
surements and conventional radiographs of the spine in all
but a few patients. Another strength of our study is the
blinded assessment of all spinal radiographs for vertebral
fractures by two experienced independent observers using
Genant’s standardized semiquantitative method, advo-
cated by the International Osteoporosis Foundation for
evaluation of vertebral fractures in the clinic (35), rather
than relying on routinely obtained radiology reports
shown to often underestimate the true prevalence of frac-
tures (25). In most other studies in liver transplantation so
far reported, (semi-)quantitative assessments were per-
formed by one observer (1, 7, 29, 30) or the method of
evaluationofvertebral fractures is notmentioned (5,6,19,
33). A further strength of our study is the inclusion of the
mild grade 1 vertebral fractures in the evaluation of prev-
alent fractures.
A limitation of our study is its retrospective design.
However, the laboratory, radiological, and densitometric
investigations were not randomly undertaken, but formed
an integral part of a preplanned pretransplantation
screening protocol for skeletal complications performed
in patients with end-stage liver failure, who in this case
went on to receive a liver transplant. Although most can-
didates for liver transplantation were screened for skeletal
complications, we only studied those who subsequently
received a liver transplant, which may have led to an un-
derestimate of the true prevalence of skeletal pathology
because the excluded patients would have been more likely
to have had the more severe liver disease and thus poten-
tially the more severe skeletal complications. We also
chose to exclude patients using corticosteroids and/or
bisphosphonates, which could also have led to the exclu-
sion of patients with the worst skeletal pathology. How-
ever, because this was the case in a relatively small number
of patients, this is unlikely to have affected the outcome of
our study. The absence of prior spinal radiographs pre-
cluded the identification of the precise time of occurrence
of a documented fracture, resulting in the association be-
tween BMD and prevalent fractures being potentially lim-
ited by the time lag between the development of a fracture
and BMD measurement. We could collect no reliable data
on nonvertebral fractures because these were poorly doc-
umented. However, previous studies report a generally
low incidence of these fractures in end-stage liver disease
(2, 5, 6, 8, 19, 29).
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In conclusion, our finding of increased fracture risk
independent of BMD in liver transplant recipients at the
time of screening for transplantation adds to the accumu-
lating body of evidence of the contributory role of bone
quality rather than just bone quantity to fracture risk in
patients with liver disease. This finding has significant
clinical implications in the evaluation and management of
prospective liver transplant recipients because it suggests
that spinal radiographs should be routinely performed in
these patients to enable identification of vertebral frac-
tures and thus of skeletal fragility. Whether this pretrans-
plantation skeletal fragility persists, worsens, or improves
after liver transplantation and whether bone fragility
could be modulated by available bone-modifying agents
to decrease or prevent skeletal morbidity after transplan-
tation remains to be established by long-term studies spe-
cifically addressing the issue of skeletal health in liver
transplant recipients.
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